Company intelligence / Profile preview

Lucia Bio

Brisbane, Queensland, Australialinkedin.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Lucia Bio was launched in late 2024 as a spin-out from the University of Queensland’s School of Biomedical Sciences. The company focuses on developing novel therapies targeting neuroinflammation to benefit patients with degenerative diseases. It has received $1 million in seed funding and represents the first new entity under Molecule to Medicine's expansion into Australia. No clinical results have been reported yet as programs are preclinical.[1][2][3]

Therapeutic areas: ImmunologyNeurology
Modalities: Small molecules (anti-inflammatory therapeutics)
Industry: Biotech

Partnerships

UniQuest/University of QueenslandMTM ecosystem partnership for biotech innovation[2][3]

Beyond the preview

Go deeper on Lucia Bio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Lucia Bio.

Explore the full profile